▁and ▁later ▁with ▁Sir ▁Greg ▁Winter . ▁He ▁was ▁Director ▁of ▁the ▁Le eds ▁Institute ▁of ▁M ole cular ▁Medicine ▁in ▁ 2 0 0 7 - 2 0 1 2 ▁and ▁moved ▁to ▁the ▁University ▁of ▁Oxford ▁ ▁to ▁become ▁Professor ▁of ▁M ole cular ▁Im mun ology ▁at ▁the ▁M RC ▁We ather all ▁Institute ▁of ▁M ole cular ▁Medicine . ▁He ▁has ▁been ▁Professor ▁of ▁M ole cular ▁Im mun ology ▁in ▁the ▁Division ▁of ▁Can cer ▁Th era pe ut ics ▁at ▁the ▁Institute ▁of ▁Can cer ▁Research , ▁London ▁since ▁ 2 0 2 0 . ▁ ▁His ▁experience ▁in ▁bi ote chn ology ▁includes ▁chair ing ▁the ▁Scient ific ▁Ad vis ory ▁Board ▁of ▁Cambridge ▁Ant ib ody ▁Technology ▁from ▁its ▁launch ▁until ▁its ▁IP O , ▁of ▁Qu adr ant ▁Health care ▁until ▁its ▁ac quisition ▁by ▁El an , ▁and ▁he ▁was ▁an ▁S AB ▁member ▁of ▁Dom ant is ▁until ▁ac quisition ▁by ▁G SK , ▁and ▁a ▁Board ▁member ▁of ▁A pt us can ▁until ▁its ▁ac quisition ▁by ▁Av act a , ▁though ▁he ▁remains ▁on ▁the ▁Scient ific ▁Ad vis ory ▁Board ▁of ▁Av act a . ▁He ▁is ▁a ▁co - found er ▁of ▁two ▁start - up ▁companies , ▁Or bit ▁Disc overy ▁and ▁of ▁Qu ad ru cept ▁Bio . ▁▁ ▁His ▁research ▁has ▁foc uss ed ▁on ▁ant ib ody ▁gene ▁divers ity , ▁gene ▁re arr ang ement ▁and ▁aber rant ▁re arr ang ement ▁of